Global Information
회사소개 | 문의 | 비교리스트

유전자 검사 시장 : 세계 시장 예측 및 분석(용도별, 기술별), 코로나19(COVID-19)의 영향, Executive/Consultant 가이드(2020-2024년)

Genetic Testing. Global Market Forecasts for Applications and Technologies. Updated for COVID-19 Pandemic impact With Executive and Consultant Guides 2020 to 2024

리서치사 Howe Sound Research
발행일 2020년 06월 상품 코드 940592
페이지 정보 영문 429 Pages
가격
US $ 6,995 ₩ 7,818,000 PDF (Single User License) help
DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로 1대의 PC에서만 이용할 수 있는 라이선스로 인쇄가 불가능합니다.
US $ 10,495 ₩ 11,730,000 PDF (Five User License) help
DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로 5대의 PC에서만 이용할 수 있는 라이선스로 인쇄가 불가능합니다.
US $ 13,995 ₩ 15,642,000 PDF (Enterprise License) help
동일기업 내 모든 분들이 이용할 수 있는 라이선스입니다. 편집 및 인쇄는 가능하며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.

주의 : 본 보고서는 DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로, 라이선스에 따라 자료 이용 및 인쇄 등에 제약이 있을 수 있습니다. 자세한 내용은 라이선스 설명문( )을 참고하여 주시기 바랍니다.



유전자 검사 시장 : 세계 시장 예측 및 분석(용도별, 기술별), 코로나19(COVID-19)의 영향, Executive/Consultant 가이드(2020-2024년) Genetic Testing. Global Market Forecasts for Applications and Technologies. Updated for COVID-19 Pandemic impact With Executive and Consultant Guides 2020 to 2024
발행일 : 2020년 06월 페이지 정보 : 영문 429 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

유전자 검사(Genetic Testing)의 향후 기술 발전 및 시장 성장 전망에 대해 분석했으며, 기술 개요 및 주요 활용 분야, 향후 의료 현장에 미치는 영향력, 최근의 주요 개발 및 제품 출시 동향, 주요 기업 프로파일과 주력 제품, 향후 시장 규모 동향 전망, 지역별·용도별·기술별 상세 동향, 코로나19(COVID-19) 발생의 영향 등의 정보를 정리하여 전해드립니다.

목차

I.유전자 검사 시장 : 전략적 상황 분석 및 코로나19(COVID-19)의 영향

ii. 임원 마케팅·판매·사업 개발 직원을 위한 제안

(iii) 경영 컨설턴트 자문을 위한 제안

제1장 서론 시장의 정의

제2장 시장 개요

  • 시장 참가자들은 다양한 역할을 수행
    • 공급업체/제약회사
    • 독립 검사실 : 전문별/난치병
    • 독립 검사실 : 국가/지역별
    • 독립 검사실 : 분석
    • 국영/공영 검사실
    • 병원 검사실
    • 진료 검사실
    • DTC 검사실
    • 독립계 유전자 검사실
    • 감사기관
  • 유전자 검사 - 종류, 사례, 고찰
    • 착상전 유전자 진단 - 신흥 시장
    • 태아진단 - 새로운 기술이 기회를 창출
    • 신생아 검사
    • 진단 검사
    • 보균자 검사
    • 예측진단/발병전 검사
    • 약리유전체학
    • 포렌식 검사
    • 친자검사(Parental Testing)
    • 조상찾기 유전자 검사(Ancestral Testing)
  • 산업 구조
    • 병원의 검사 점유율
    • 규모의 경제
    • 내과의원
    • 의사와 POCT
  • 주요 유전학 기업의 시장 점유율 - 분석

제3장 시장 동향

  • 시장 성장 촉진요인
  • 시장 성장 억제요인
  • 계측 및 자동화
  • 진단 기술 개발
    • 차세대 시퀀싱(NGS) : 혁명의 촉진
    • NGS의 가격 책정에 대한 영향
    • POCT/자가검사의 파괴력파괴적 검사 방법
    • 약리유전체학 : 진단과 치료의 일체화
    • CGES 테스트 : 신세계 개척
    • 바이오칩/거대 자기저항 기반 분석

제4장 유전자 검사 : 최근의 진척 상황

  • 본 섹션의 중요성과 활용 방법

제5장 주요 기업 개요

  • 10x Genomics, Inc
  • 23andME Inc
  • Abbott Diagnostics
  • AccuraGen Inc.
  • Adaptive Biotechnologies
  • Admera Health, LLC
  • Agena Bioscience, Inc
  • Agilent
  • Akonni Biosystems
  • Ancestry.com LLC
  • Anchor Dx
  • ArcherDx, Inc.
  • ARUP Laboratories
  • Asuragen
  • Baylor Miraca Genetics Laboratories
  • Beckman Coulter, Inc.
  • Becton, Dickinson and Company
  • BGI Genomics Co. Ltd
  • Bioarray Genetics
  • Biocept, Inc
  • Biodesix Inc.
  • BioFluidica
  • BioGenex
  • Biolidics Ltd
  • bioM & eacute; rieux Diagnostics
  • Bioneer Corporation
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne
  • Cancer Genetics
  • Caris Molecular Diagnostics
  • CellMax Life
  • Centogene
  • Chronix Biomedical
  • Circulogene
  • Clinical Genomics
  • Color Genomics
  • Complete Genomics, Inc.-A BGI Company
  • Cynvenio
  • Dante Labs
  • Datar Cancer Genetics Limited
  • Diasorin SpA
  • Epic Sciences
  • Epigenomics AG
  • Eurofins Scientific
  • Excellerate Bioscience
  • Exosome Diagnostics
  • Fabric Genomics
  • Fluidigm Corp
  • Foundation Medicine
  • Freenome
  • FUJIFILM Wako Diagnostics
  • Fujirebio
  • GE Global Research
  • GE Healthcare Life Sciences
  • Gene by Gene, Ltd
  • Genedrive
  • GeneFirst Ltd
  • Genetron Health(Beijing) Co., Ltd.
  • Genewiz
  • Genomic Health
  • Genomics England
  • Genomics Personalized Health(GPH)
  • GenomOncology
  • Genzyme Corporation
  • Grail, Inc
  • Grifols
  • Guardant Health
  • Guardiome
  • HeiScreen
  • Helix
  • Helomics
  • Hologic
  • Horizon Discovery
  • HTG Molecular Diagnostics
  • Human Longevity, Inc.
  • iCellate
  • Illumina
  • Incell Dx
  • Inivata
  • Integrated Diagnostics
  • Invitae Corporation
  • Invivoscribe
  • Karius
  • Macrogen
  • MDNA Life SCIENCES, Inc
  • MDx Health
  • Medgenome
  • Meridian Bioscience
  • Mesa Biotech
  • MIODx
  • miR Scientific
  • MNG Labs
  • Molecular MD
  • NantHealth, Inc.
  • Natera
  • Nebula Genomics
  • NeoGenomics
  • New Oncology
  • Novogene Bioinformatics Technology Co., Ltd
  • Omega Bioservices
  • OncoDNA
  • ORIG3N, Inc.
  • Origene Technologies
  • Oxford Nanopore Technologies
  • Pacific Biosciences
  • Panagene
  • Perkin Elmer
  • Personal Genome Diagnostics
  • Personalis
  • Precipio
  • PrecisionMed
  • Promega
  • Protagen Diagnostics
  • Qiagen Gmbh
  • Quantumdx
  • Regeneron
  • Roche Molecular Diagnostics
  • Roswell Biotechnologies
  • Seegene
  • Sequencing.com
  • Siemens Healthineers
  • simfo GmbH
  • Singlera Genomics Inc
  • SkylineDx
  • Stratos Genomics
  • Sure Genomics, Inc.
  • Sysmex
  • Sysmex Inostics
  • Tempus Labs, Inc.
  • Thermo Fisher Scientific Inc
  • Veritas Genetics
  • Volition

제6장 세계 시장 규모

  • 국가별 분석 : 개요
  • 용도별 분석 : 개요
  • 기술별 분석 : 개요

제7장 용도별 시장 규모

  • 신생아 검사
  • 비침습적 산전 기형아 검사(NIPT)
  • 예측 검사
  • 종양 검사
  • DTC(Direct to Consumer)
  • 기타

제8장 유전자 검사 시장 : 기술별

  • PCR 검사
  • 차세대 시퀀싱(NGS)
  • 세포유전학적 검사
  • 기타

제9장 유전자 검사의 미래

부록

LSH 20.06.24

Table of Tables

  • Table 1: Most Common Traditional Genetic Disorders
  • Table 2: Lab Spending 2014 to 2024
  • Table 3: Market Players by Type
  • Table 4: The Different Types of Genetic Tests
  • Table 5: Five Factors Driving Growth
  • Table 6: Four Factors Limiting Growth
  • Table 7: Key Diagnostic Laboratory Technology Trends
  • Table 8: Next Generation Sequencing Technologies - Speed and Cost
  • Table 9: Global Market by Country
  • Table 10: Global Market by Application
  • Table 11: Global Market by Technology
  • Table 12: Newborn Segment by Country
  • Table 13: NIPT Segment by Country
  • Table 14: Predictive Segment by Country
  • Table 15: Oncology Segment by Country
  • Table 16: DTC Segment by Country
  • Table 17: Other Segment by Country
  • Table 18: PCR Segment by Country
  • Table 19: NGS Segment by Country
  • Table 20: Cytogenetic Segment by Country
  • Table 21: Other Segment by Country
  • Table 22: 2020 CLINICAL LAB FEE SCHEDULE

Table of Figures

  • Figure 1: Clinical Lab Spending 2014 to 2024
  • Figure 2: Top Ten Sequencing Companies
  • Figure 3: Percentage of World Population Over 65
  • Figure 4: Key Countries
  • Figure 5: Application Share by Year
  • Figure 6: Application Segment Growth Rates
  • Figure 7: Segment Share Shifts
  • Figure 8: Application Segment Share Base Year
  • Figure 9: Application Segment Share Final Year
  • Figure 10: Technology Share by Year
  • Figure 11: Technology Segment Growth Rates
  • Figure 12: Technology Segment Share Shifts
  • Figure 13: Technology Segment Share Base Year
  • Figure 14: Technology Segment Share Final Year
  • Figure 15: Newborn vs. Total Market Growth
  • Figure 16: NIPT vs. Total Market Growth
  • Figure 17: Predictive vs. Total Market Growth
  • Figure 18: Oncology vs. Total Market Growth
  • Figure 19: DTC vs. Total Market Growth
  • Figure 20: Other vs. Total Market Growth
  • Figure 21: PCR vs. Total Market Growth
  • Figure 22: NGS vs. Total Market Growth
  • Figure 23: Cytogenetic vs. Total Market Growth
  • Figure 24: Other vs. Total Market Growth

OVERVIEW:

Large genetic testing cancer segment impacted by COVID-19. Genetic Blizzard creating confusing array of new tests.

Will all newborns receive Whole Genomic Sequencing at birth? What has happened to Direct to Consumer?

The role of genetics in health and disease is just now being understood. This new knowledge, combined with lower pricing is driving the Genetic Testing industry to record growth. New drugs may only work for people with a certain genetic makeup, and this too is driving the Genetic Testing Industry. The traditional genetic testing market is growing in volume and growing in the breadth of tests creating new life for the industry. The report forecasts the market size out to 2024. The report includes detailed breakouts for 14 countries and 5 regions.

Predictive Diagnostics? Pharmacogenomic Testing? Direct to Consumer? Find out about the technology in readily understood terms that explain the jargon. What are the issues? Find the opportunities and the pitfalls. Understand growth expectations and the ultimate market forecasts for the next five years.

All report data is available in Excel format on request.

Make investment decisions and valuations with confidence using the latest data.

ABOUT THE LEAD AUTHOR:

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

  • B.Sc. (Chemistry) University of BC
  • M.B.A. (Finance and Policy) University of BC
  • Market Research Seminar - Burke Institute
  • Finance for Senior Executives - Harvard Business School

Table of Contents

i. Genetic Testing - Strategic Situation Analysis & Impact of COVID-19 Pandemic

ii. Guide for Executives, Marketing, Sales and Business Development Staff

iii. Guide for Management Consultants and Investment Advisors

1. Introduction and Market Definition

  • 1.1. Genetic Testing Definition in This Report
  • 1.2. The Genomics Revolution
  • 1.3. Market Definition
    • 1.3.1. Revenue Market Size
    • 1.3.1. Newborn Screening
    • 1.3.2. Non Invasise Pregnancy Testing
    • 1.3.3. Predictive
    • 1.3.4. Oncology
    • 1.3.5. Direct to Consumer
    • 1.3.6. Other Application
    • 1.3.7. PCR
    • 1.3.4. NGS
    • 1.3.5. Cytogenetic
    • 1.3.6. Other Technology
  • 1.4. U.S. Medical Market and laboratory Testing - Perspective
    • 1.4.1. U.S. Medicare Expenditures for Laboratory Testing

2. Market Overview

  • 2.1. Market Participants Play Different Roles
    • 2.1.1. Supplier/pharmaceutical
    • 2.1.2. Independent lab specialized/esoteric
    • 2.1.3. Independent lab national/regional
    • 2.1.4. Independent lab analytical
    • 2.1.5. Public National/regional lab
    • 2.1.6. Hospital lab
    • 2.1.7. Physician lab
    • 2.1.8. DTC Lab
    • 2.1.9. Independent Genetic Testing Lab
    • 2.1.10. Audit Body
  • 2.2. Genetic Tests -Types, Examples and Discussion
    • 2.2.1. Preimplantation Genetic Diagnosis- An Emerging Market
    • 2.2.2. Prenatal Diagnosis-New Technologies Create Opportunity
    • 2.2.3. Newborn Screening
    • 2.2.2. Diagnostic Testing
    • 2.2.3. Carrier Testing
    • 2.2.6. Predictive and Presymptomatic Testing
    • 2.2.7. Pharmacogenomics
    • 2.2.8. Forensic Testing
    • 2.2.9. Parental Testing
    • 2.2.10. Ancestral Testing
  • 2.3. Industry Structure
    • 2.3.1. Hospital's Testing Share
    • 2.3.2. Economies of Scale
      • 2.3.2.1. Hospital vs. Central Lab
    • 2.3.3. Physician Office Lab's
    • 2.3.4. Physician's and POCT
  • 2.4. Market Shares of Key Genetics Players - Analysis

3. Market Trends

  • 3.1. Factors Driving Growth
    • 3.1.1. Genetic Discoveries Creating New Diagnostic Markets
    • 3.1.2. Aging Population a Boon for Diagnostics
    • 3.1.3. Pharmacogenomics Drives Further Growth.
    • 3.1.4. Oncology and Liquid Biopsy Enter New Era
    • 3.1.5. Fertility Practice Growth drives market
    • 3.1.6. Direct to Consumer begins to break out
  • 3.2. Factors Limiting Growth
    • 3.2.1. Increased Competition Lowers Price
    • 3.2.2. Lower Costs
    • 3.2.3. Testing usage analysis curtailing growth.
    • 3.2.4. Wellness has a downside
  • 3.3. Instrumentation and Automation
    • 3.3.1. Instruments Key to Market Share
    • 3.3.2. Bioinformatics Plays a Role.
  • 3.4. Diagnostic Technology Development
    • 3.4.1. Next Generation Sequencing Fuels a Revolution.
    • 3.4.2. Impact of NGS on pricing
    • 3.4.3. POCT/Self Testing Disruptive Force
    • 3.4.4. Pharmacogenomics Blurs Diagnosis and Treatment
    • 3.4.5. CGES Testing, A Brave New World
    • 3.4.6. Biochips/Giant magneto resistance based assay

4. Genetic Testing Recent Developments

  • 4.1.1. Importance of This Section
  • 4.1.2. How to Use This Section
    • Preconception Carrier Screening Trial Begins in Australia
    • Genetic Testing Clinical Use Just Beginning
    • Fulgent Genetics Q1 Revenues Jump 44 Percent
    • Blueprint Genetics, NICER Consortium Developing Genetic Test for Immunologic,
    • Hematologic Disorders
    • Natera Terminates Qiagen Agreement for Developing NGS-Based Genetic Tests
    • Invitae Acquires Three Companies: YouScript, Genelex, Diploid
    • Thermo Fisher Scientific to Buy Qiagen for $11.5B
    • PerkinElmer SCID Test Chosen for Newborn Screening Evaluation in England
    • Germline Cancer Risk Mutations Sometimes Reported in Tumor Testing
    • Blueprint Genetics, Archimedlife to Launch Genetic Testing in North America
    • Invitae to Offer No-Charge Genetic Testing to Pancreatic Cancer Patients
    • Phosphorus Offers DNA Testing to Assess Disease Risk
    • Arivale Shuts Down Personalized Wellness Business
    • ArcherDX Acquires Baby Genes
    • MDxHealth, LifeLabs Ink Distribution Agreement for Prostate Cancer Assay
    • Thermo Fisher Purchases 9 Percent Stake in Yourgene Health
    • Invitae Partners to Expand Free Epilepsy Genetic Testing Program
    • Illumina, Chinese Firm Partner on NGS System for Genetic Disease Dx
    • NanoString Technologies Prices $103.5M Common Stock Offering
    • Canine Consumer Genomics Firm Embark Veterinary Raises $10M
    • Yourgene Health to Acquire Elucigene
    • Helix, AdventHealth Partner on Genetic Screening Study
    • Qiagen, NeuMoDx Ink Partnership, Merger Agreement

5. Profiles of Key Companies

  • 10x Genomics, Inc
  • 23andME Inc
  • Abbott Diagnostics
  • AccuraGen Inc.
  • Adaptive Biotechnologies
  • Admera Health, LLC
  • Agena Bioscience, Inc
  • Agilent
  • Akonni Biosystems
  • Ancestry.com LLC
  • Anchor Dx
  • ArcherDx, Inc.
  • ARUP Laboratories
  • Asuragen
  • Baylor Miraca Genetics Laboratories
  • Beckman Coulter, Inc.
  • Becton, Dickinson and Company
  • BGI Genomics Co. Ltd
  • Bioarray Genetics
  • Biocept, Inc
  • Biodesix Inc.
  • BioFluidica
  • BioGenex
  • Biolidics Ltd
  • bioMérieux Diagnostics
  • Bioneer Corporation
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne
  • Cancer Genetics
  • Caris Molecular Diagnostics
  • CellMax Life
  • Centogene
  • Chronix Biomedical
  • Circulogene
  • Clinical Genomics
  • Color Genomics
  • Complete Genomics, Inc.-A BGI Company
  • Cynvenio
  • Dante Labs
  • Datar Cancer Genetics Limited
  • Diasorin S.p.A.
  • Epic Sciences
  • Epigenomics AG
  • Eurofins Scientific
  • Excellerate Bioscience
  • Exosome Diagnostics
  • Fabric Genomics
  • Fluidigm Corp
  • Foundation Medicine
  • Freenome
  • FUJIFILM Wako Diagnostics
  • Fujirebio
  • GE Global Research
  • GE Healthcare Life Sciences
  • Gene by Gene, Ltd
  • Genedrive
  • GeneFirst Ltd
  • Genetron Health (Beijing) Co., Ltd.
  • Genewiz
  • Genomic Health
  • Genomics England
  • Genomics Personalized Health (GPH)
  • GenomOncology
  • Genzyme Corporation
  • Grail, Inc
  • Grifols
  • Guardant Health
  • Guardiome
  • HeiScreen
  • Helix
  • Helomics
  • Hologic
  • Horizon Discovery
  • HTG Molecular Diagnostics
  • Human Longevity, Inc.
  • iCellate
  • Illumina
  • Incell Dx
  • Inivata
  • Integrated Diagnostics
  • Invitae Corporation
  • Invivoscribe
  • Karius
  • Macrogen
  • MDNA Life SCIENCES, Inc
  • MDx Health
  • Medgenome
  • Meridian Bioscience
  • Mesa Biotech
  • MIODx
  • miR Scientific
  • MNG Labs
  • Molecular MD
  • NantHealth, Inc.
  • Natera
  • Nebula Genomics
  • NeoGenomics
  • New Oncology
  • Novogene Bioinformatics Technology Co., Ltd
  • Omega Bioservices
  • OncoDNA
  • ORIG3N, Inc.
  • Origene Technologies
  • Oxford Nanopore Technologies
  • Pacific Biosciences
  • Panagene
  • Perkin Elmer
  • Personal Genome Diagnostics
  • Personalis
  • Precipio
  • PrecisionMed
  • Promega
  • Protagen Diagnostics
  • Qiagen Gmbh
  • Quantumdx
  • Regeneron
  • Roche Molecular Diagnostics
  • Roswell Biotechnologies
  • Seegene
  • Sequencing.com
  • Siemens Healthineers
  • simfo GmbH
  • Singlera Genomics Inc
  • SkylineDx
  • Stratos Genomics
  • Sure Genomics, Inc.
  • Sysmex
  • Sysmex Inostics
  • Tempus Labs, Inc.
  • Thermo Fisher Scientific Inc
  • Veritas Genetics
  • Volition

6. Global Market Size

  • 6.1. Global Market by Country
    • 6.1.1. Table-Global Market by Country
    • 6.1.2. Chart-Key Country Densities
  • 6.2. Global Market by Application
    • 6.2.1. Table-Global Market by Application
    • 6.2.2. Chart-Application Share by Year
    • 6.2.3. Chart-Application Segment Growth Rates
    • 6.2.4. Chart-Application Segment Share Shifts
    • 6.2.5. Chart-Application Segment Share Base Year
    • 6.2.6. Chart-Application Segment Share Final Year
  • 6.3. Global Market by Technology
    • 6.3.1. Table-Global Market by Technology
    • 6.3.2. Chart-Technology Share by Year
    • 6.3.3. Chart-Technology Segment Growth Rates
    • 6.3.4. Chart-Technology Segment Share Shifts
    • 6.3.5. Chart-Technology Segment Share Base Year
    • 6.3.6. Chart-Technology Segment Share Final Year

7. Market Sizes by Application

  • 7.1. Newborn Testing Market
    • 7.1.1. Table Newborn-by Country
    • 7.1.2. Chart-Newborn Growth
  • 7.2. NIPT Market
    • 7.2.1. Table NIPT-by Country
    • 7.2.2. Chart-NIPT Growth
  • 7.3. Predictive Testing Market
    • 7.3.1. Table Predictive-by Country
    • 7.3.2. Chart-Predictive Growth
  • 7.4. Oncology Testing Market
    • 7.4.1. Table Oncology-by Country
    • 7.4.2. Chart-Oncology Growth
  • 7.5. DTC Testing Market
    • 7.5.1. Table DTC-by Country
    • 7.5.2. Chart-DTC Growth
  • 7.6. Other Testing Market
    • 7.6.1. Table Other-by Country
    • 7.6.2. Chart-Other Growth

8. Global Genetic Testing Market by Technology

  • 8.1. PCR Testing Market
    • 8.1.1. Table PCR-by Country
    • 8.1.2. Chart-PCR Growth
  • 8.2. NGS Market
    • 8.2.1. Table NGS-by Country
    • 8.2.2. Chart-NGS Growth
  • 8.3. Cytogenetic Testing Market
    • 8.3.1. Table Cytogenetic-by Country
    • 8.3.2. Cytogenetic-Predictive Growth
  • 8.4. Other Testing Market
    • 8.4.1. Table Other-by Country
    • 8.4.2. Chart-Other Growth

9. The Future of Genetic Testing

Appendices

  • I. United States Medicare System: January 2020 laboratory Fees Schedule
  • II Methodology
    • II.1 Authors
    • II.2 Sources
Back to Top
전화 문의
F A Q